Threshold Levels of Monocyte Chemoattractant-1 for Determining Phenotypes of Children with Cerebral Palsy

Aim of the Study. To establish threshold levels of monocyte chemoattractant -1 for determining phenotypes in children with cerebral palsy (CP).

Material and Methods. The work was carried out in the period from 2018 to 2022 at the Department of Faculty Pediatrics of the Federal State Budgetary Educational Institution of Higher Education Astrakhan State Medical University of the Ministry of Health of the Russian Federation, State Budgetary Healthcare Institution of the Astrakhan Region N.N. Silishcheva Regional Children’s Clinical Hospital, and State Autonomous Institution of the Astrakhan Region Astrakhan Regional Children’s Clinical Center Rus. The study involved 128 children with different clinical forms of cerebral palsy. The level of monocyte chemoattractant1 was determined by enzyme immunoassay using a diagnostic reagent kit from Vector-Best (Novosibirsk). Statistical analysis was performed using IBM SPSS Statistics 26.0 (USA).

Results and Discussion Based on the conducted examination, two phenotypes of children with cerebral palsy were distinguished. Among children of the first phenotype, higher concentrations of monocyte chemoattractant-1 in the blood serum were revealed. Thus, in patients of the first phenotype it was 2.1 (1.63; 2.99) pg/ml, which was statistically significantly (p<0.001) higher than in children of the second phenotype, 1.71 (1.44; 2.06) pg/ml. Using ROC analysis, the threshold level of monocyte chemoattractant-1 for determining belonging to the first or second phenotype was identified. It was 1.89 pg/ml. If the values exceed the specified one, the patient can be attributed to the first phenotype, with lower or equal values — to the second phenotype. CONCLUSION As a result of the conducted studies, a threshold level of MCP-1 was identified, amounting to 1.89 pg/ml. In patients of the first phenotype, possessing the most unfavorable prognostic characteristics, the values of monocyte chemoattractant-1 are higher than the specified indicator, which allows for the organization of rehabilitation measures at an earlier date. Keywords: cerebral palsy, monocyte chemoattractant, comorbid pathology> < 0.001) higher than in children of the second phenotype, 1.71 (1.44; 2.06) pg/ml. Using ROC analysis, the threshold level of monocyte chemoattractant-1 for determining belonging to the first or second phenotype was identified. It was 1.89 pg/ml. If the values exceed the specified one, the patient can be attributed to the first phenotype, with lower or equal values — to the second phenotype.

Conclusion. As a result of the conducted studies, a threshold level of MCP-1 was identified, amounting to 1.89 pg/ml. In patients of the first phenotype, possessing the most unfavorable prognostic characteristics, the values of monocyte chemoattractant-1 are higher than the specified indicator, which allows for the organization of rehabilitation measures at an earlier date.

1. Tkachenko E.S., Goleva O.P., Sherbakov D.V., Khalikova A.R. Cerebral Palsy: The State of Knowledge of the Problem (Review). Mother and Baby in Kuzbass. 2019;2:4–9.

2. Graham HK, Rosenbaum P, Paneth N, Dan B, Lin JP, Damiano DL, et al. Cerebral palsy. Nat Rev Dis Primers. 2016;2:15082. PMID: 27188686 https://doi.org/10.1038/nrdp.2015.82

3. Vitrikas K, Dalton H, Breish D. Cerebral Palsy: An Overview. Am Fam Physician. 2020;101(4):213–220. PMID: 32053326

4. Wu Y, Tang J, Chen Y, Huang Y. Social-Emotional Development and Associated Risk Factors in Chinese Toddlers with Cerebral Palsy. Neuropsychiatr Dis Treat. 2021;17:2451–2463. PMID: 34335026 https://doi.org/10.2147/NDT.S308138

5. Kuznetsova ED, Adil’zhanova MA. Osobennosti kommunikativnykh navykov doshkol’nikov s detskim tserebral’nym paralichom. In: Sovremennaya logopediya: mezhdu traditsiyami i novatsiyami v kontekste problem spetsial’nogo i inklyuzivnogo obrazovaniya (Sankt-Peterburg, 5- 6 oktyabrya 2023): sb. tezisov. Saint Petersburg; 2023. pp. 14–121. (In Russ.) Available at: https://www.herzen.spb.ru/upload/medialibrary/1a0/xhr7ek285n26kvbg7169bmkn2ua0cu3c/Sbornik-materialov.pdf [Accessed Aug 19, 2025]

6. Salkov VN, Khudoerkov RM. Infantile Cerebral Palsy as a Result of Prenatal Brain Dysontogenesis. Russian Bulletin of Perinatology and Pediatrics. 2019;64(3):11–16. (In Russ.) https://doi.org/10.21508/1027-4065-2019-64-3-11-16

7. Chan SJ, Love C, Spector M, Cool SM, Nurcombe V, Lo EH. Endogenous regeneration: Engineering growth factors for stroke. Neurochem Int. 2017;107:57–65. PMID: 28411103 https://doi.org/10.1016/j.neuint.2017.03.024

8. Nurzhanova ZM, Shilova AA, Bashkina OA, Samotrueva MA. Estimation of the Level of Endothelial Factor of Vascular Growth and Monocytic Chemoattractant in Children Cerebral Palsy. Humans and Their Health. 2021;24(3):33–38. (In Russ.) https://doi.org/10.21626/vestnik/2021-3/04

9. Nurzhanova ZM, Bashkina OA, Samotrueva MA, Shilova AA. Pathogenetic Role of Monocyte Chemoattractant. Doctor.ru. 2023;22(7):53–57. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-7-53-57

10. Batiushin MM, Gadaborsheva KhZ. Monocyte Chemoattractant Protein-1: Its Role in the Development of Tubulointerstitial Fibrosis in Nephropathies. Medical News of North Caucasus. 2017;12(2):234–239. https://doi.org/10.14300/mnnc.2017.12067

11. Huie JR, Diaz-Arrastia R, Yue JK, Sorani MD, Puccio AM, Okonkwo DO, et al. Testing a multivariate proteomic panel for traumatic brain injury biomarker discovery: A TRACK-TBI Pilot Study. J Neurotrauma. 2019;36(1):100–110. PMID: 30084741 https://doi.org/10.1089/neu.2017.5449

12. Afonin AA, Lebedenko AA, Panova IV, Berezhanskaya SB, Afonina TA, Sozaeva DI, et al. The Role of Monocytic Chemoattractant Protein-1 in the Violation of the Blood-Brain Barrier and the Formation of Cerebral Pathology. Modern Problems of Science and Education. 2022;(6-2):8. https://doi.org/10.17513/spno.32117